Development of Vaccines Based on Formulations Containing Nonionic Block Copolymers
This chapter focuses on the capacity of vaccine formulations containing synthetic nonionic block polymers to modify or augment immune responses to current vaccines and some vaccines under development. These polymers are surface-active agents that can be formulated alone with antigens or as part of hydrophobic delivery vehicles. In current licensed human vaccines, improvements can be made to increase vaccine immunogenicity so that they can be administered in fewer injections, or so that seroconversion rates can be increased in target populations. Subunit antigen vaccines under development can lack potency, which can be significantly enhanced if formulated with an adjuvant or given in the appropriate delivery system. The capacity to induce a protective immune response can be induced by incorporating immunogens into delivery systems. These delivery systems include molecules and preparations classified as adjuvants, antigen encapsulation strategies, antigen targeting techniques, pulsatile release vehicles, live vectors, and other systems.
KeywordsInfluenza Vaccine Triblock Copolymer Seroconversion Rate Vaccine Formulation Adjuvant Activity
Unable to display preview. Download preview PDF.
- Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R. M., 1991, Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin neutralizing antibodies, Infect. Immun. 59:2978–2986.PubMedGoogle Scholar
- Good, M. F., Pombo, D., Lunde, M. N., Maloy, W. L., Halenbeck, R., Koths, K., Miller, L. H., and Berzofsky, J. A., 1988a, Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2, J. Immunol. 141:972–977.PubMedGoogle Scholar
- Good, M. F., Pombo, D., Quakyi, I. A., Riley, E. M., Houghten, R. A., Menon, A., Alling, D. W., Berzofsky, J. A., and Miller, L. H., 1988b, Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule, Proc. Natl. Acad. Sci. USA 85:1199–1203.PubMedCrossRefGoogle Scholar
- Haigwood, N. L., Nara, P. L., Brooks, E., Van Nest, G., Ott, G., Higgins, K. W., Dunlop, N., Scandella, C. J., Eichberg, J. W., and Steimer, K. S., 1992, Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons, J. Virol. 66:172–182.PubMedGoogle Scholar
- Hilleman, M. R., 1967, Considerations for safety and application of emulsified oil adjuvants to viral vaccines, in: International Symposium on Adjuvants of Immunity, Utrecht, 1966, Karger, Basel, pp. 13–26.Google Scholar
- Hunter, R. L., Kidd, M. R., Olsen, M. R., Patterson, P. S., and Lal, A. A., 1994, Induction of long-lasting immunity to P. yoelii malaria using whole blood-stage antigen and copolymer adjuvants, (submitted).Google Scholar
- Institute of Medicine Committee on the Children’s Vaccine Initiative, 1993, The Children’s Vaccine Initiative (V. S. Mitchell, N. M. Philipose, and J. P. Sanford, eds.), National Academy Press, Washington, DC.Google Scholar
- Livingston, P. O., Adluri, S., Raychaudhuri, S., Hughes, M. H., Calves, M. J., and Merritt, J. A., 1994, A phase I trial of the immunological adjuvant SAFm in melanoma patients vaccinated with the anti-idiotype antibody MELIMMUNE™, Vaccine Res. 3:71–81.Google Scholar
- Page, W. F., Norman, J. E., and Benenson, A. S., 1993, Long-term follow-up of army recruits immunized with Freund’s incomplete adjuvanted vaccine, Vaccine Res. 2:141–149.Google Scholar
- Sempertegui, F., Estrella, B., Moscoso, J., Piedrahita, L., Hernandez, D., Gaybor, J., Naranjo, P., Mancero, O., Arias, S., Bernai, R., Cordova, M. E., Suarez, J., and Zicker, F., 1994, Safety, immunogenicity and protective effect of SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador, Vaccine 12:337–342.PubMedCrossRefGoogle Scholar
- Teusher, T., Armstrong-Schellenberg, J. R. M., Bastos de Azvedo, I., Hurt, N., Smith, T., Hayes, R., Masanja, H., Silva, Y., Lopez, M. C., Kitua, A., Kilama, W., Tanner, M., and Alonzo, P. L., 1994, SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission, Vaccine 12:328–336.CrossRefGoogle Scholar